Sarepta Therapeutics
SRPT
#4401
Rank
โ‚น209.54 B
Marketcap
โ‚น2,000
Share price
-2.45%
Change (1 day)
-81.30%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

Sarepta Therapeutics (SRPT) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚น195.24 Billion

According to Sarepta Therapeutics 's latest financial reports the company's total liabilities are โ‚น195.24 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Sarepta Therapeutics - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น208.92 B4.34%
2023-12-31โ‚น200.23 B-11.8%
2022-12-31โ‚น227.01 B37.39%
2021-12-31โ‚น165.23 B1.64%
2020-12-31โ‚น162.57 B126.93%
2019-12-31โ‚น71.64 B68.02%
2018-12-31โ‚น42.63 B28.73%
2017-12-31โ‚น33.12 B457.6%
2016-12-31โ‚น5.94 B7.13%
2015-12-31โ‚น5.54 B84.65%
2014-12-31โ‚น3.00 B9.53%
2013-12-31โ‚น2.74 B-38.42%
2012-12-31โ‚น4.45 B260.42%
2011-12-31โ‚น1.23 B-43.5%
2010-12-31โ‚น2.18 B29.46%
2009-12-31โ‚น1.68 B258.39%
2008-12-31โ‚น0.47 B-2.03%
2007-12-31โ‚น0.48 B244.67%
2006-12-31โ‚น0.13 B12.85%
2005-12-31โ‚น0.12 B26.93%
2004-12-31โ‚น97.42 M-42.95%
2003-12-31โ‚น0.17 B-30.47%
2002-12-31โ‚น0.24 B55.15%
2001-12-31โ‚น0.15 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Gilead Sciences
GILD
โ‚น3.330 T 1,606.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น120.07 B-38.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
โ‚น22.27 B-88.59%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚น74.95 B-61.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น414.84 B 112.48%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
โ‚น251.49 B 28.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
โ‚น127.13 B-34.88%๐Ÿ‡บ๐Ÿ‡ธ USA